New Ways to Treat Advanced Prostate Cancer
Mechanisms of Androgen Receptor Inverse Agonists in Advanced Prostate Cancer
This research looks for new ways to stop advanced prostate cancer from growing by changing how cancer cells respond to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11133052 on NIH RePORTER |
What this research studies
When prostate cancer becomes resistant to standard hormone therapy, it's called metastatic castration-resistant prostate cancer (mCRPC), which is much more aggressive. This project aims to understand how cancer cells become resistant by studying the "Androgen Receptor" and other proteins that drive tumor growth. Researchers are developing new molecules that can switch the Androgen Receptor's function, making it suppress the genes that normally help tumors grow. This work uses advanced lab models that closely mimic human tumors to find out how these new treatments work at a molecular level.
Who could benefit from this research
Good fit: This research is relevant for adult patients with advanced prostate cancer, especially those whose cancer has become resistant to hormone therapy.
Not a fit: Patients whose prostate cancer is still responsive to standard hormone therapy may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to entirely new treatments for advanced prostate cancer that overcome current drug resistance.
How similar studies have performed: This approach involves novel molecules and mechanisms, building on new evidence about how prostate cancer becomes resistant to treatment.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Gryder, Berkley E — Case Western Reserve University
- Study coordinator: Gryder, Berkley E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.